B. Strom

First name
B.
Middle name
L.
Last name
Strom
Lewis, J. D., Gelfand, J. M., Troxel, A. B., Forde, K. A., Newcomb, C., Kim, H., et al. (2008). Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. http://doi.org/10.1111/j.1572-0241.2008.01836.x
View
Flory, J. H., Ellenberg, S., Szapary, P. O., Strom, B. L., & Hennessy, S. (2009). Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. http://doi.org/10.2337/dc08-1809
View
Re, 3rd. L., Haynes, K., Ming, E. E., Ives, W., Horne, L. N., Fortier, K., et al. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318
View
Leonard, C. E., Freeman, C. P., Newcomb, C. W., Reese, P. P., Herlim, M., Bilker, W. B., et al. (2012). Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3329
View
Carbonari, D. M., Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., et al. (2015). Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3844
View
Saine, M. E., Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K., Roy, J. A., et al. (2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z
View
Saine, M. E., Gizaw, M., Carbonari, D. M., Newcomb, C. W., Roy, J. A., Cardillo, S., et al. (2017). Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4368
View
Re, L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400
View
Saine, M. E., Carbonari, D. M., Newcomb, C. W., Gallagher, A. M., Blak, B. T., Roy, J. A., et al. (2019). Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4853
View